(TSX Venture: ARI) TORONTO, Nov. 10 /CNW/ - ARIUS Research Inc. (TSX-V: ARI) today announced that a group of novel anti-cancer antibodies in their collaboration with Protein Design Labs, Inc. (PDL) has met another research objective based on experiments conducted by PDL. These anti-cancer antibodies were produced through ARIUS' FunctionFIRST(TM) platform then selected by the Collaboration in early 2005 to move forward. Now, successful and timely completion of this second objective means these antibodies have met the next requirement for licensing. The three-year collaboration was originally announced in 2003. Under the agreement, ARIUS was paid an upfront technology access fee to support their research efforts and to fund generation of new, anti-cancer antibodies using its proprietary FunctionFIRST(TM) platform. ARIUS will receive licensing fees, milestone payments, and a percentage royalty on any licensed antibody. "We are excited and pleased by these new data from PDL," said Dr. David Young, President of ARIUS Research Inc. "Their efforts and commitment to our collaboration are building considerable value into the antibodies and helping with their rapid progress." Interest in functional anti-cancer antibodies has grown since the release of studies this year that showed an improvement in survival for breast cancer patients who were treated with the antibody, Herceptin. The overall antibody market has been forecast to reach $12 billion by 2008. The ARIUS/PDL collaboration has the potential to develop antibodies for multiple types of cancers. About ARIUS Research ARIUS Research Inc. is a biotechnology company dedicated to the discovery and development of novel anticancer monoclonal antibodies (MAbs). Established in 1999, ARIUS has built a proprietary technology platform, FunctionFIRST(TM), that rapidly identifies powerful MAbs targeting a variety of cancer indications. This antibody generation engine has enabled ARIUS to assemble a growing pipeline of over 300 functional MAbs, which may be used for commercial collaborations, out-licensing or in-house development. ARIUS has ongoing licensing and research partnerships with key biotechnology and drug development companies that provide revenues and access to external technologies. The long-term vision of ARIUS is to deliver personalized therapy by matching multiple antibodies to the distinct antigenic characteristics of each patient's tumor cells thereby increasing efficacy and avoiding side effects. ARIUS is listed on the TSX Venture Exchange under the symbol "ARI". Forward-Looking Statement Certain statements in this news release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, which involve known and unknown risks, uncertainties and other factors that may cause our actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Forward-looking statements in this release include, but are not limited to, ARIUS successfully advancing its new product programs as well as licensing opportunities. These statements are only predictions and actual events or results may differ materially. Factors that could cause such actual events or results expressed or implied by such forward-looking statements to differ materially from any future results expressed or implied by such statements include, but are not limited to: early stage of development; technology and product development; dependence on and management of current and future corporate collaborations; future capital needs; uncertainty of additional funding; no assurance of market acceptance; dependence on proprietary technology and uncertainty of patent protection; intense competition; manufacturing and market uncertainties; and government regulation. These and other factors are described in detail in the Company's Annual Report, forthcoming news releases and other filings with Canadian securities regulatory authorities and the U.S. Securities & Exchange Commission. Forward-looking statements are based on our current expectations and ARIUS is not obligated to update such information to reflect later events or developments. Website: www.ariusresearch.com The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement.